PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 141 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $563,380 | -29.0% | 214,213 | -4.7% | 0.00% | -50.0% |
| Q2 2023 | $793,519 | +47.7% | 224,793 | +29.3% | 0.00% | +100.0% |
| Q1 2023 | $537,091 | -60.5% | 173,816 | -45.9% | 0.00% | -66.7% |
| Q4 2022 | $1,358,917 | +12.6% | 321,257 | -19.1% | 0.00% | +50.0% |
| Q4 2021 | $1,207,000 | +640.5% | 396,967 | +1605.5% | 0.00% | +100.0% |
| Q3 2021 | $163,000 | -69.0% | 23,276 | +71.4% | 0.00% | -50.0% |
| Q1 2019 | $526,000 | +118.3% | 13,576 | +15.1% | 0.00% | 0.0% |
| Q4 2018 | $241,000 | -16.6% | 11,796 | +141.1% | 0.00% | -50.0% |
| Q2 2018 | $289,000 | -44.4% | 4,892 | -72.4% | 0.00% | -20.0% |
| Q1 2016 | $520,000 | -93.0% | 17,700 | -81.4% | 0.01% | -92.9% |
| Q4 2015 | $7,445,000 | +90.9% | 94,965 | +475.1% | 0.07% | +37.3% |
| Q1 2015 | $3,899,000 | +527.9% | 16,513 | +75.4% | 0.05% | +466.7% |
| Q2 2014 | $621,000 | – | 9,416 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 200,000 | $20,706,000 | 6.01% |
| Redmile Group, LLC | 230,673 | $23,882,000 | 2.95% |
| WEATHERBIE CAPITAL, LLC | 241,419 | $24,994,000 | 2.31% |
| Tekla Capital Management LLC | 185,820 | $19,238,000 | 2.02% |
| Ghost Tree Capital, LLC | 25,000 | $2,588,000 | 1.59% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $588,741,000 | 1.56% |
| Iguana Healthcare Management, LLC | 25,000 | $2,588,000 | 1.48% |
| Eventide Asset Management | 42,100 | $4,359,000 | 1.34% |
| Bain Capital Public Equity Management, LLC | 401,330 | $41,550,000 | 1.17% |
| Rock Springs Capital Management LP | 31,500 | $3,261,000 | 1.16% |